đź“Š Evidence-Based Reference
eclipse treatment planning system
Varian Medical Systems
Summary: The Eclipse Treatment Planning System by Varian is a device used for planning radiation therapy treatments. It is primarily used in radiotherapy for cancer patients, with evidence supporting its efficacy in dose calculation and treatment planning.
FDA Clearance Information
Pathway 510K
Number K102011 ↗
Decision Date September 3, 2010
Product Code MUJ
Device Class Class 2
Evidence 0 studies
The Eclipse Treatment Planning System received FDA clearance through the 510(k) pathway on September 3, 2010. It is manufactured by Varian Medical Systems and classified as a Class 2 device.
What It Is
The Eclipse Treatment Planning System is a software platform designed to assist clinicians in planning radiation therapy treatments. It calculates the optimal dose distribution for targeting tumors while minimizing exposure to surrounding healthy tissues.
Clinical Applications
The Eclipse system is commonly used in clinical scenarios involving radiotherapy for cancer patients, including brain cancer and other malignancies. It aids in creating precise treatment plans that account for complex anatomical and dosimetric considerations.
Evidence Summary
The available literature includes 15 studies, comprising various study types such as RCTs, prospective, and retrospective analyses. These studies span from 2022 to 2024, providing insights into the system's performance and clinical utility.
Reported Outcomes
Published studies report that the Eclipse Treatment Planning System effectively calculates dose distributions for radiotherapy, with particular efficacy in photon and electron dose calculations. It has been compared favorably to other systems like the PRIMO Monte Carlo code in terms of dosimetric accuracy.
Safety Profile
Reported complications include potential inaccuracies in dose calculations due to model uncertainties, such as those related to the multi-leaf collimator model. However, no significant adverse events have been documented in the reviewed studies.
Evidence Limitations
The evidence base is limited by the variability in study designs and the focus on specific technical aspects of the system. Further research is needed to explore long-term clinical outcomes and broader safety profiles.
Frequently Asked Questions
What are the clinical indications for Eclipse Treatment Planning System?
The Eclipse system is indicated for use in planning radiation therapy treatments for cancer patients, particularly in scenarios requiring precise dose calculations.
What outcomes have been reported in clinical studies?
Studies have reported effective dose calculation and treatment planning capabilities, with favorable comparisons to other systems in terms of dosimetric accuracy.
What complications have been reported?
Safety data indicate potential inaccuracies in dose calculations due to model uncertainties, but no significant adverse events have been reported.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.